PHARMAKON ADVISORS
Pharmakon Advisors is a New York-based investment company that offers financing solutions to commercial stage, biotechnology companies.
PHARMAKON ADVISORS
Status:
Active
Similar Organizations
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that provides funding to life sciences startups.
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-03-08 | UroGen Pharma | Pharmakon Advisors investment in Post-IPO Debt - UroGen Pharma | 100 M USD |
2022-01-07 | Coherus Biosciences | Pharmakon Advisors investment in Post-IPO Debt - Coherus Biosciences | 100 M USD |
2021-12-14 | Evolus | Pharmakon Advisors investment in Post-IPO Debt - Evolus | 125 M USD |
2020-12-08 | BRAINBox Solutions | Pharmakon Advisors investment in Series A - BRAINBox Solutions | 23 M USD |
2020-09-12 | OptiNose | Pharmakon Advisors investment in Post-IPO Debt - OptiNose | 150 M USD |
2019-12-13 | Sarepta Therapeutics | Pharmakon Advisors investment in Post-IPO Debt - Sarepta Therapeutics | 250 M USD |
2019-11-12 | Akebia Therapeutics | Pharmakon Advisors investment in Post-IPO Debt - Akebia Therapeutics | 100 M USD |
2016-01-05 | Halozyme Therapeutics | Pharmakon Advisors investment in Post-IPO Debt - Halozyme Therapeutics | 150 M USD |
2015-03-13 | Assertio | Pharmakon Advisors investment in Post-IPO Debt - Assertio | 575 M USD |
2014-07-28 | PaxVax | Pharmakon Advisors investment in Debt Financing - PaxVax | 50 M USD |
More informations about "Pharmakon Advisors"
Pharmakon Advisors - Crunchbase Investor Profile
Pharmakon Advisors is a New York-based investment company that offers financing solutions to commercial stage, biotechnology companies. New York , New York , United States 1-10See details»
Pharmakon Advisors - Investments, Portfolio & Company Exits
Pharmakon Advisors is a New York-based investment company that offers financing solutions to commercial stage, biotechnology companies. Search Crunchbase. ... How many investments …See details»
Pharmakon Advisors - Investor Profile, Portfolio & Team - Tracxn
Nov 13, 2024 Co-investors of Pharmakon Advisors. Over the past . 15 years, 19 investors have co-invested in Pharmakon Advisors's portfolio companies.. This includes funds and …See details»
Fenwick Represents Pharmakon Advisors in its $400 Million …
May 2, 2024 Fenwick represented Pharmakon Advisors, a leading investor in non-dilutive debt for the life sciences industry, in IP diligence in Pharmakon’s up to $400 million funding …See details»
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive …
May 2, 2024 We are pleased to again partner with Pharmakon on this transaction.” Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the …See details»
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive …
Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds. Established in 2009, funds …See details»
Pharmakon Advisors, LP (New York) | Adviser Rankings - wallmine
Pharmakon Advisors, LP is a large advisory firm based in New York. It manages $1.91 billion of regulatory assets for 11 client accounts. It has been registered with the SEC as an adviser …See details»
Pharmakon Advisors - Crunchbase
Pharmakon Advisors is a New York-based investment company that offers financing solutions to commercial stage, biotechnology companies. Search Crunchbase. Start Free Trial . Chrome …See details»
Investor Materials - Pharmakon Advisors, LP
Investor materials available on the Pharmakon Advisors, LP website. Disclaimer The content of this website is provided by the Adviser and offers information about the Adviser and its …See details»
Pharmakon Advisors - Overview, News & Similar companies
Apr 22, 2024 Who is Pharmakon Advisors. Pharmakon Advisors, LP is the investment manager of the BioPharma Credit funds and of BioPharma Credit PLC (LON:BPCR). the only listed …See details»
Pharmakon Advisors, Lp in New York, NY - U.S. News
Pharmakon Advisors, Lp is a national financial advisory firm headquartered in New York, NY. The firm has $3.1 billion under management.The firm caters to 5 clients of varying types. Assets …See details»
Pharmakon Advisors Company Profile: Financings & Team
Pharmakon Advisors General Information Description. Established in 2009, Pharmakon Advisors is a lender based in New York City, New York. The firm provides debt financing facilities such …See details»
Geron Corporation Announces up to $375 Million in Funding With …
San Francisco – November 7, 2024 – Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course …See details»
Epizyme Announces Expanded Loan Facility with Pharmakon …
Nov 6, 2020 About Pharmakon Advisors Pharmakon Advisors, LP is the investment manager of the BioPharma Credit funds and of BioPharma Credit PLC (LON:BPCR), the only listed …See details»
Press Release Archives - Pharmakon Advisors, LP
Disclaimer The content of this website is provided by Pharmakon Advisors, LP (“Pharmakon”) and offers information about Pharmakon and its affiliates and a general overview of its investment …See details»
Pharmakon Advisors - Contacts, Employees, Board Members, …
Pharmakon Advisors is a New York-based investment company that offers financing solutions to commercial stage, biotechnology companies. Search Crunchbase. Start Free Trial . Chrome …See details»
Insmed Announces Strategic Financings Totaling $775 Million
Oct 19, 2022 Akin Gump Strauss Hauer & Feld LLP acted as counsel to Pharmakon Advisors, LP on the Term Loan. Morrison & Foerster LLP acted as counsel to OrbiMed on the Royalty …See details»
Evolus Enters Into $125 Million Credit Facility with Pharmakon …
Dec 14, 2021 Evolus, a performance beauty company, has entered into a $125 million term loan financing facility with funds managed by Pharmakon Advisors, L.P.See details»
Epizyme Establishes Agreements for Up to $270 Million in Funding …
Nov 4, 2019 Under a separate agreement, Epizyme has established a $70 million loan facility with Pharmakon Advisors, an affiliate of Royalty Pharma, which will fund the regulatory …See details»